TCTR20200526013尚未招募未知
The 28-day Mortality Outcome of the complete Hour-1 Sepsis Bundle in Emergency Department
Ramathibodi hospital Mahidol university0 个研究点目标入组 556 人开始时间: 2020年5月26日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 发起方
- 入组人数
- 556
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 19 Years 至 0 N/A (No limit)（—）
- 性别
- All
入选标准
- •1. Age > 18 years old
- •2. Initial diagnosis of sepsis or septic shock
- •3. Ramathibodi Emergency Department visit
- •4. Ramathibodi sepsis protocol used
排除标准
- •1. Refusal of treatment
- •2. do-not-attempt-resuscitation orders
- •3. Refer out to another hospital at later
- •4. Previous diagnosis or treatment of sepsis
研究者
相似试验
进行中（未招募）
1 期
Evaluation of the efficacy and safety of QVA149 (110/50 µg o.d.) vs tiotropium (18 µg o.d.) + salmeterol/fluticasone propionate FDC (50/500 µg b.i.d.) in patients with moderate to severe COPDEUCTR2015-000114-22-GRovartis Pharma Services AG1,000
进行中（未招募）
1 期
Evaluation of the efficacy and safety of QVA149 (110/50 µg o.d.) vs tiotropium (18 µg o.d.) + salmeterol/fluticasone propionate FDC (50/500 µg b.i.d.) in patients with moderate to severe COPDChronic Obstructive Pulmonary Disease (COPD)MedDRA version: 19.0Level: LLTClassification code 10010952Term: COPDSystem Organ Class: 100000004855EUCTR2015-000114-22-NLovartis Pharma Services AG1,000
进行中（未招募）
1 期
Evaluation of the efficacy and safety of QVA149 (110/50 µg o.d.) vs tiotropium (18 µg o.d.) + salmeterol/fluticasone propionate FDC (50/500 µg b.i.d.) in patients with moderate to severe COPDChronic Obstructive Pulmonary Disease (COPD)MedDRA version: 19.1Level: LLTClassification code 10010952Term: COPDSystem Organ Class: 100000004855EUCTR2015-000114-22-DKovartis Pharma Services AG1,000
进行中（未招募）
1 期
Evaluation of the efficacy and safety of QVA149 (110/50 µg o.d.) vs tiotropium (18 µg o.d.) + salmeterol/fluticasone propionate FDC (50/500 µg b.i.d.) in patients with moderate to severe COPDChronic Obstructive Pulmonary Disease (COPD)MedDRA version: 19.0Level: LLTClassification code 10010952Term: COPDSystem Organ Class: 100000004855EUCTR2015-000114-22-HRovartis Pharma Services AG1,000
进行中（未招募）
1 期
Evaluation of the efficacy and safety of QVA149 (110/50 µg o.d.) vs tiotropium (18 µg o.d.) + salmeterol/fluticasone propionate FDC (50/500 µg b.i.d.) in patients with moderate to severe COPDChronic Obstructive Pulmonary Disease (COPD)MedDRA version: 20.0Level: LLTClassification code 10010952Term: COPDSystem Organ Class: 100000004855EUCTR2015-000114-22-PLovartis Pharma Services AG1,000